Welcome to Angion Biomedica. We are a clinical stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, cure disease and save lives by modulating the body's protective, reparative and regenerative systems. We aim to provide therapeutic solutions for unmet medical needs in acute tissue injury, fibrosis and cancer.

Our discovery and development efforts have yielded a rich and diverse product pipeline comprising novel, small molecule modulators of the HGF pathway, PARP-1 enzyme inhibitors, Relaxin analogs, LPA1 receptor antagonists, receptor tyrosine kinase inhibitors, modulators of retinoic acid signaling and steroid biosynthesis inhibitors that are in advanced preclinical or clinical development.

• Angion’s first-in-class HGF mimetic enters Phase II clinical trials for renal and cardiac indications.
• Angion relocates to fully integrated facility in Uniondale, NY.
• Angion Biomedica Enters Multi-Institutional Alliance to Advance Novel and Promising Therapies for Ischemic Stroke.
• Angion Biomedica's drug BB3 receives both Fast Track and Orphan Drug designations from FDA.